Why BioNTech Stock Was Sliding Today
BioNTech (NASDAQ: BNTX) shares were having an atypically bad day on Wednesday, and by the close of trading were down by nearly 7%. A downshift in one analyst's recommendation seems to be the latest headwind buffeting the company's stock.
Analyst Simon Baker at Redburn Securities changed his recommendation on the stock to sell from neutral, tagging it with a $146 per share target price. That's nearly 30% below its current level.
Image source: Getty Images.
Source Fool.com